Saudi FDA Releases New Regulatory Guidance for Drug Submissions and Applications – Effective January 1, 2027

The Saudi Food & Drug Authority (SFDA), Drug Sector, has issued a new document titled Regulatory Guidance for Submissions and Applications, Version 1.0, dated October 14, 2026. The guidance will come into effect on January 1, 2027.

This updated guidance aims to streamline drug registration procedures, improve regulatory submission management, and clarify the requirements for obtaining, varying, renewing, or discontinuing marketing authorizations in Saudi Arabia.

Key Highlights of the New SFDA Guidance

The document covers several important aspects of pharmaceutical regulatory affairs, including:

• New Marketing Authorization Applications (MAA): Procedures and requirements for submitting drug registration applications.

• Variations of Marketing Authorization: Classification and submission requirements for minor and major variations.

• Marketing Authorization Renewal: Requirements for renewing product registrations every five years, with renewal applications to be submitted at least six months before certificate expiry.

• Electronic Submissions: Requirements for electronic Common Technical Document (eCTD) submissions for human medicinal products, CTD submissions for herbal and health products, and VNeeS submissions for veterinary products.

• Priority Review and Accelerated Pathways: Guidance on priority review, rolling submissions, verification and abridged pathways, breakthrough medicine designation, and orphan drug applications.

• Regulatory Review Timelines: Performance targets and procedures for responding to regulatory inquiries and providing additional documentation.

• Application Validation: Technical and business validation processes designed to ensure submissions are complete and ready for scientific assessment.

What Does This Mean for Pharmaceutical Companies?

Pharmaceutical manufacturers, marketing authorization holders, exporters, and regulatory affairs professionals planning to register or maintain medicinal products in Saudi Arabia should carefully review the new guidance and assess its impact on their existing regulatory processes.

Companies should prepare their regulatory documentation, submission procedures, and internal compliance activities well in advance of the implementation date.

Important: The new guidance replaces the previous Regulatory Framework for Drugs Approval and Guidance for Submission Guideline documents as the primary reference for drug application submissions, according to the SFDA publication.

Official Reference

Document: Regulatory Guidance for Submissions and Applications
Authority: Saudi Food & Drug Authority (SFDA) – Drug Sector
Version: 1.0
Date of Issue: October 14, 2026
Effective Date: January 1, 2027
Document Reference: DS-G-144-V01/261014

Stay updated with Pharmatext for pharmaceutical regulatory news, GMP guidance, drug registration updates, and industry developments.

Disclaimer: This article is an informational summary of the referenced SFDA guidance. Companies should consult the official document and applicable SFDA requirements before making regulatory decisions.

Download Free

#SFDA #SaudiFDA #PharmaceuticalRegulatoryAffairs #DrugRegistration #PharmaRegulatory #SaudiArabia #MarketingAuthorization #eCTD #CTD #RegulatoryCompliance #PharmaceuticalIndustry #DrugApproval #RegulatoryUpdates #PharmaNews #Pharmatext